Skip to main content
. 2020 Apr 25;22:91. doi: 10.1186/s13075-020-02161-8

Table 3.

Therapeutic approach for thirty-one cSLE patients at the beginning of the study

Total, n = 31 n (%)
Cyclophosphamide 17 (55.0)
Azathioprine 13 (42.0)
Mycophenolate mofetil 13 (42.0)
Rituximab 3 (9.6)
Immunoglobulins 5 (16.0)
Tacrolimus 3 (9.6)
Methotrexate 1 (3.2)
Hydroxychloroquine 31 (100.0)